ID: ALA610997

Max Phase: Preclinical

Molecular Formula: C10H16N2O5

Molecular Weight: 244.25

Molecule Type: Small molecule

Representations

Canonical SMILES:  O=C1NCC=CCN1C1O[C@H](CO)[C@@H](O)[C@H]1O

Standard InChI:  InChI=1S/C10H16N2O5/c13-5-6-7(14)8(15)9(17-6)12-4-2-1-3-11-10(12)16/h1-2,6-9,13-15H,3-5H2,(H,11,16)/t6-,7-,8-,9?/m1/s1

Standard InChI Key:  HBBIVXDEBCKFIZ-BYBOBHAWSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 244.25

Molecular Weight (Monoisotopic): 244.1059

AlogP: -1.99

#Rotatable Bonds: 2

Polar Surface Area: 102.26

Molecular Species: NEUTRAL

HBA: 5

HBD: 4

#RO5 Violations: 0

HBA (Lipinski): 7

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 0

CX Acidic pKa: 12.52

CX Basic pKa:

CX LogP: -2.12

CX LogD: -2.12

Aromatic Rings: 0

Heavy Atoms: 17

QED Weighted: 0.42

Np Likeness Score: 1.77

References

1. Liu PS, Marquez VE, Driscoll JS, Fuller RW, McCormack JJ..  (1981)  Cyclic urea nucleosides. Cytidine deaminase activity as a function of aglycon ring size.,  24  (6): [PMID:7252974] [10.1021/jm00138a003]

2. Chung SJ, Fromme JC, Verdine GL..  (2005)  Structure of human cytidine deaminase bound to a potent inhibitor.,  48  (3): [PMID:15689149] [10.1021/jm0496279]

Source

Source(1):

• Scientific Literature